Vident Advisory, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Vident Advisory, LLC
- $3.62 Trillion
- Q2 2024
A detailed history of Vident Advisory, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 1,749 shares of ALNY stock, worth $468,714. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,749
Previous 1,561
12.04%
Holding current value
$468,714
Previous $233 Million
82.18%
% of portfolio
0.01%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ALNY
# of Institutions
614Shares Held
108MCall Options Held
2.33MPut Options Held
2.17M-
Capital World Investors Los Angeles, CA15MShares$4.01 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.35 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.56 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.66 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.62 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...